Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGE-A3 ASCI + Dacarbazine in Metastatic Melanoma
NCT00849875Phase 2Terminated
- Sponsor
- GSK
- Start
- May 2009
- Primary completion
- Nov 2014
- Modality
- Vaccines & Immunotherapeutics, Peptides, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of astuprotimut-R in cutaneous melanoma (CM), sponsored by GSK. Started May 2009; status: terminated.
02
Drugs
astuprotimut-R
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT00849875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00849875.